Stock Track | Sarepta Therapeutics Plunges 5.38% After-Hours on Disappointing Q1 Revenue and ELEVIDYS Sales Decline

Stock Track05-07

Sarepta Therapeutics' stock experienced a significant after-hours plunge of 5.38% following the release of its first-quarter 2026 financial results.

The decline was driven by a 2% year-over-year drop in quarterly revenue to $730.8 million, primarily attributed to a sharp 73% decrease in sales of its therapy ELEVIDYS. The company cited an updated product label restricting use to ambulatory patients as a key factor behind the lower sales volume for this treatment.

While the company reported a positive swing to net income of $331 million and reiterated its full-year 2026 net product revenue guidance of $1.2-$1.4 billion, investors reacted negatively to the revenue shortfall and the significant decline in its flagship ELEVIDYS product sales during the quarter.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1130507881?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 05:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130507881","market":"us","top_or_hot":-1,"title":"Stock Track | Sarepta Therapeutics Plunges 5.38% After-Hours on Disappointing Q1 Revenue and ELEVIDYS Sales Decline","media":"Stock Track","content":"<p>Sarepta Therapeutics' stock experienced a significant after-hours plunge of 5.38% following the release of its first-quarter 2026 financial results.</p><p>The decline was driven by a 2% year-over-year drop in quarterly revenue to $730.8 million, primarily attributed to a sharp 73% decrease in sales of its therapy ELEVIDYS. The company cited an updated product label restricting use to ambulatory patients as a key factor behind the lower sales volume for this treatment.</p><p>While the company reported a positive swing to net income of $331 million and reiterated its full-year 2026 net product revenue guidance of $1.2-$1.4 billion, investors reacted negatively to the revenue shortfall and the significant decline in its flagship ELEVIDYS product sales during the quarter.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Sarepta Therapeutics Plunges 5.38% After-Hours on Disappointing Q1 Revenue and ELEVIDYS Sales Decline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Sarepta Therapeutics Plunges 5.38% After-Hours on Disappointing Q1 Revenue and ELEVIDYS Sales Decline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-07 05:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sarepta Therapeutics' stock experienced a significant after-hours plunge of 5.38% following the release of its first-quarter 2026 financial results.</p><p>The decline was driven by a 2% year-over-year drop in quarterly revenue to $730.8 million, primarily attributed to a sharp 73% decrease in sales of its therapy ELEVIDYS. The company cited an updated product label restricting use to ambulatory patients as a key factor behind the lower sales volume for this treatment.</p><p>While the company reported a positive swing to net income of $331 million and reiterated its full-year 2026 net product revenue guidance of $1.2-$1.4 billion, investors reacted negatively to the revenue shortfall and the significant decline in its flagship ELEVIDYS product sales during the quarter.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SRPT","symbol_name":"Sarepta Therapeutics","start_time":0,"source_url":"","article_id":"1130507881","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130507881","pubTimestamp":1778101374,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Sarepta Therapeutics' stock experienced a significant after-hours plunge of 5.38% following the release of its first-quarter 2026 financial results.The decline was driven by a 2% year-over-year drop...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SRPT":"Sarepta Therapeutics"},"translate_title":"个股追踪|Sarepta Therapeutics盘后暴跌5.38%，Q1营收令人失望，ELEVIDYS销量下滑","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRPT":1},"content_text":"Sarepta Therapeutics' stock experienced a significant after-hours plunge of 5.38% following the release of its first-quarter 2026 financial results.The decline was driven by a 2% year-over-year drop in quarterly revenue to $730.8 million, primarily attributed to a sharp 73% decrease in sales of its therapy ELEVIDYS. The company cited an updated product label restricting use to ambulatory patients as a key factor behind the lower sales volume for this treatment.While the company reported a positive swing to net income of $331 million and reiterated its full-year 2026 net product revenue guidance of $1.2-$1.4 billion, investors reacted negatively to the revenue shortfall and the significant decline in its flagship ELEVIDYS product sales during the quarter.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130507881","isCrawlerRequest":true}